Tulmimetostat

Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor that targets and inhibits the EZH2 enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies[1][2][3][4].

Product Specifications

CAS Number

[2567686-02-4]

Product Name Alternative

CPI-0209

UNSPSC

12352005

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tulmimetostat.html

Concentration

10mM

Purity

99.79

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C2C(O[C@@](O2)([C@]3([H])CC[C@](N4CC(C4)OC)([H])CC3)C)=C(C=C1C(NCC5=C(C=C(NC5=O)C)SC)=O)Cl

Molecular Formula

C28H36ClN3O5S

Molecular Weight

562.12

References & Citations

[1]WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022.|[2]Drescher C, et al. EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) : preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC) 2023.|[3]Morschhauser F, et al. Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood Rev. 2022 Nov;56:100988.|[4]Qiu J, et al. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020 Aug;12 (15) :1415-1430.|[5]Rentian Wu, et al. Abstract 2126: Therapeutic potential of CPI-0209. Cancer Res 1 July 2021; 81 (13_Supplement) : 2126.